Literature DB >> 1645516

Mammographic localization and biopsy of nonpalpable breast lesions. A 5-year study.

W R Thompson1, J R Bowen, B A Dorman, V E Pricolo, T K Shahinian, C H Soderberg.   

Abstract

A malignancy rate of 24% was achieved as a result of needle localizations and biopsies of 548 nonpalpable mammographically detected breast lesions in 507 consecutive patients during a 5-year period. Malignancy was present in 74 (23.8%) of 311 irregular soft-tissue densities, in 40 (19.6%) of 204 cases with clustered microcalcifications, and in 33 cases (54.5%) when both features were present. Same-day admission and discharge were achieved in 491 patients and local anesthesia supplemented with intravenous sedation was used in 73 (74%) of the 98 patients (in 1989) by the end of the study period. Nonpalpable cancers were categorized pathologically as stage 0 in 25 patients (20.8%), stage I in 67 patients (55.8%), stage IIA in 24 patients (20.0%), and stage IIB in four patients (3.3%). The malignancy rate rose sharply from the fourth to the fifth decade.

Entities:  

Mesh:

Year:  1991        PMID: 1645516     DOI: 10.1001/archsurg.1991.01410300076011

Source DB:  PubMed          Journal:  Arch Surg        ISSN: 0004-0010


  3 in total

1.  Is needle-directed breast biopsy overused?

Authors:  M W Shields; R S Smith; M F Bardwil; J K Harness
Journal:  West J Med       Date:  1994-03

2.  Image-guided core-needle breast biopsy is an accurate technique to evaluate patients with nonpalpable imaging abnormalities.

Authors:  G M Fuhrman; G J Cederbom; J S Bolton; T A King; J L Duncan; J L Champaign; D H Smetherman; G H Farr; R R Kuske; W M McKinnon
Journal:  Ann Surg       Date:  1998-06       Impact factor: 12.969

3.  Diagnostic accuracy for different strategies of image-guided breast intervention in cases of nonpalpable breast lesions.

Authors:  R M Pijnappel; M van den Donk; R Holland; W P Th M Mali; J L Peterse; J H C L Hendriks; P H M Peeters
Journal:  Br J Cancer       Date:  2004-02-09       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.